The main purpose of this research group is to have significant pharmacological expertise and knowledge in the field of clinical drug trials, with regard to efficacy, safety and performance. Current research area; cardiovascular and inflammatory disorders, pain and transplant medicine. 

Aims

To create optimal pharmacological treatment opportunities for our patient groups based on multidisciplinary clinical studies.

• The HEMMER study; to study the effect of the changing degree of uraemia between dialysis sessions on CYP3A activity in patients receiving haemodialysis
• LidoPOp; development of a pharmacokinetic population model for lidocaine and the metabolite MEGX undergoing major surgery
• Substitution of R,S-methadone with R-methadone in methadone maintenance treatment patients with known prolonged QT-time; in order to map changes in QTc time by transition from (R, S) methadone to R methadone in patients with known prolonged QTc time
• CyPed-study;  to study CYP3A activity and to investigate the impact of CYP3A inhibitors in pediatric patients
• Optimal management of patients with atrial fibrillation (AF); to study the correlation between paroxysmal atrial fibrillation (PAF) and sleep apnea (SA) and that treatment of SA will reduce the overall burden of AF as well as reduce the recurrence rate of AF after pulmonary vein ablation

Contact information:
Hasse Khiabani Zaré 
Department of Pharmacology, Oslo University Hospital, Rikshospitalet, PO Box 4956 Nydalen, NO-0424 Oslo, Norway
Tel +47 905 43 878 E-mail: haskhi@ous-hf.no

Contact information:
Hasse Khiabani Zaré 
Department of Pharmacology, Oslo University Hospital, Rikshospitalet, PO Box 4956 Nydalen, NO-0424 Oslo, Norway
Tel +47 905 43 878 E-mail: haskhi@ous-hf.no